secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001628280-25-053318
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna targets up to 10% revenue growth in 2026; closes $1.5B loan facility
----------------------------------------------------------------------------

- Targets up to 10% revenue growth in 2026; expanding seasonal vaccine franchise to up to six approved products by 2028.
- Reducing 2026 and 2027 GAAP operating expenses by ~$0.5B each year on path to cash breakeven in 2028.
- Closed a five-year $1.5B term loan facility from Ares Management Credit Funds; initial draw $0.6B.
- Discontinues four pipeline programs: CMV, HSV, VZV, and GSD1a; advances nine oncology Phase 2/3 studies.
- Updated 2025 year-end cash guidance to $7.1-$7.6B (from $6.5-$7.0B) due to loan draw.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000162828025053318/0001628280-25-053318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000162828025053318/mrna-20251120.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-053318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer